Studying the effect of endotracheal tube replacement in the treatment of ventilator- associated pneumonia

Studying the effect of endotracheal tube replacement in the treatment of ventilator- associated pneumonia in patients admitted to the intensive care unit

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251109067927N1

Enrollment

Registered

2026-03-31

Start date

2026-04-21

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator associated pneumonia. Ventilator associated pneumonia

Interventions

Intervention 1: Control group: The control group receives routine ICU care, and the endotracheal tube of all patients is replaced as needed—specifically in cases of obstruction due to secretions—by a

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients older than 18 years old who have developed ventilator-associated pneumonia with cpis >6

Exclusion criteria

Exclusion criteria: Patients older than 60 years or younger than 18 years old Patients with compromised or difficult airways Patients with unstable hemodynamics status Patients with severe pulmonary contusion Patients with ARDS Patients with immunodeficiency Patients with aspiration pneumonia or necrotizing pneumonia Patients who have undergone endotracheal tube replacement for causes other than VAP

Design outcomes

Primary

Measure	Time frame
Age. Timepoint: Biggening of the trial. Method of measurement: Based on patient's file.;Sex. Timepoint: Biggening of the trial. Method of measurement: Based on the patient's file.;Underlying diseases. Timepoint: Biggening of the trial. Method of measurement: Based on the patient's file.;Duration of the treatment. Timepoint: At the end of the trial. Method of measurement: Based on the patient's file.;Complications of pneumonia. Timepoint: At the biggening and the end of the trial. Method of measurement: Chest X-Ray, CT Scan, clinical examination.;Number of days under ventilation. Timepoint: At the end of the trial. Method of measurement: Patient's file and charts.;Duration of ICU admission. Timepoint: At the end of the trial. Method of measurement: Based on the patient's file.;Ventilator-associated pneumonia recurrence. Timepoint: At the end of the trial. Method of measurement: Clinical examination and lab results.;APACHE score 2. Timepoint: At the biggening of the trial. Method of measurement: Data collecting form.;Spo2/fio2 ratio. Timepoint: Daily. Method of measurement: Patient's file and chart.;Sepsis. Timepoint: Duration of the trial. Method of measurement: Clinical and paraclinical findings.	—

Measure

Time frame

Age. Timepoint: Biggening of the trial. Method of measurement: Based on patient's file.;Sex. Timepoint: Biggening of the trial. Method of measurement: Based on the patient's file.;Underlying diseases. Timepoint: Biggening of the trial. Method of measurement: Based on the patient's file.;Duration of the treatment. Timepoint: At the end of the trial. Method of measurement: Based on the patient's file.;Complications of pneumonia. Timepoint: At the biggening and the end of the trial. Method of measurement: Chest X-Ray, CT Scan, clinical examination.;Number of days under ventilation. Timepoint: At the end of the trial. Method of measurement: Patient's file and charts.;Duration of ICU admission. Timepoint: At the end of the trial. Method of measurement: Based on the patient's file.;Ventilator-associated pneumonia recurrence. Timepoint: At the end of the trial. Method of measurement: Clinical examination and lab results.;APACHE score 2. Timepoint: At the biggening of the trial. Method of measurement: Data collecting form.;Spo2/fio2 ratio. Timepoint: Daily. Method of measurement: Patient's file and chart.;Sepsis. Timepoint: Duration of the trial. Method of measurement: Clinical and paraclinical findings.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdiye Sharifzadeh

Kerman University of Medical Sciences

msharifzade78@gmail.com+98 34 3223 5011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026